Form 4: Cytek Biosciences SVP Philippe Busque Reports Stock Transactions

Sentiment:

SEC Form 4 Filing


Philippe Busque, SVP of Global Sales and Services at Cytek Biosciences, reports the vesting of restricted stock units and subsequent tax withholding.

Summary

  • On May 19, 2025, Philippe Busque, SVP of Global Sales and Services at Cytek Biosciences, reported transactions involving common stock and restricted stock units (RSUs).
  • Busque acquired shares through the vesting of RSUs and simultaneously had shares withheld to cover tax obligations.
  • The transactions resulted in a net change in Busque's beneficial ownership of Cytek Biosciences common stock.
  • The price for the tax withholding was $2.69.

Sentiment

Score: 5

Explanation: This is a routine regulatory filing, so the sentiment is neutral.

Industry Context

This filing is a routine disclosure related to executive compensation and stock-based awards, common in publicly traded companies. It provides transparency into the equity holdings of company insiders.

Stakeholder Impact

  • The filing provides transparency to shareholders regarding executive compensation and ownership.

Key Dates

DateDescription
05/18/2024Initial vesting date for some of the RSU awards.
08/18/2024Subsequent vesting date for some of the RSU awards.
11/18/2024Subsequent vesting date for some of the RSU awards.
03/10/2025Subsequent vesting date for some of the RSU awards.
05/18/2025Subsequent vesting date for some of the RSU awards.
05/19/2025Date of the reported transactions: RSU vesting and tax withholding.
05/21/2025Date of the Form 4 filing.
08/18/2025Future vesting date for some of the RSU awards.
11/18/2025Future vesting date for some of the RSU awards.
03/10/2026Future vesting date for some of the RSU awards.

Keywords

Cytek Biosciences, Form 4, Philippe Busque, RSU, Stock transaction, Beneficial ownership, Vesting, Tax withholding

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.